Sector News

Stryker acquires single-use device reprocessor Hygia Health Services

May 2, 2018
Life sciences

Stryker said today it acquired single-use-device reprocessor Hygia Health Services for an undisclosed amount.

Birmingham, Ala.-based Hygia has partnered with Kalamazoo, Mich.-based Stryker since 2015 to reprocess single-use devices, and Stryker said the acquisition will “further solidify the partnership.”

Stryker said that Hygia’s product portfolio of air transfer mattresses, fall alarms, ECG leads, cerebral-somatic sensors and infusor bags will help broaden its reprocessing offerings. Stryker said that it reprocessed approximately 3,000 single-use devices in 2017, with estimated savings of approximately $326 million.

“In line with our commitment to help hospitals and health systems increase the value their SUD reprocessing programs deliver, this acquisition will enhance our ability to deliver savings to our customers. Furthermore, our broader product portfolio will help customers elevate their sustainability goals and set a higher bar for sustainable healthcare delivery,” Stryker sustainability solutions prez Brian White said in a prepared statement.

Last week, Stryker saw shares fall slightly after it posted first quarter earnings that topped Wall Street expectations but saw sales shrink slightly.

By Fink Densford

Source: MassDevice

comments closed

Related News

June 3, 2023

Sanofi’s frexalimab shows early potential in in Phase II multiple sclerosis trial

Life sciences

In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.

June 3, 2023

Lonza to acquire Synaffix to strengthen ADC development

Life sciences

Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).

June 3, 2023

BD taps Novartis, GSK alum Laura Boros to lead drug delivery device business

Life sciences

In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.

How can we help you?

We're easy to reach